Suppr超能文献

采用全基因组测序对弥漫性大 B 细胞淋巴瘤进行突变和结构分析。

Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.

机构信息

Genome Sciences Centre, BC Cancer Agency, Vancouver, Canada.

出版信息

Blood. 2013 Aug 15;122(7):1256-65. doi: 10.1182/blood-2013-02-483727. Epub 2013 May 22.

Abstract

Diffuse large B-cell lymphoma (DLBCL) is a genetically heterogeneous cancer composed of at least 2 molecular subtypes that differ in gene expression and distribution of mutations. Recently, application of genome/exome sequencing and RNA-seq to DLBCL has revealed numerous genes that are recurrent targets of somatic point mutation in this disease. Here we provide a whole-genome-sequencing-based perspective of DLBCL mutational complexity by characterizing 40 de novo DLBCL cases and 13 DLBCL cell lines and combining these data with DNA copy number analysis and RNA-seq from an extended cohort of 96 cases. Our analysis identified widespread genomic rearrangements including evidence for chromothripsis as well as the presence of known and novel fusion transcripts. We uncovered new gene targets of recurrent somatic point mutations and genes that are targeted by focal somatic deletions in this disease. We highlight the recurrence of germinal center B-cell-restricted mutations affecting genes that encode the S1P receptor and 2 small GTPases (GNA13 and GNAI2) that together converge on regulation of B-cell homing. We further analyzed our data to approximate the relative temporal order in which some recurrent mutations were acquired and demonstrate that ongoing acquisition of mutations and intratumoral clonal heterogeneity are common features of DLBCL. This study further improves our understanding of the processes and pathways involved in lymphomagenesis, and some of the pathways mutated here may indicate new avenues for therapeutic intervention.

摘要

弥漫性大 B 细胞淋巴瘤(DLBCL)是一种遗传异质性癌症,由至少 2 种分子亚型组成,这些亚型在基因表达和突变分布上存在差异。最近,应用基因组/外显子测序和 RNA-seq 技术对 DLBCL 的研究揭示了许多在该疾病中经常发生体细胞点突变的基因。在这里,我们通过对 40 例新诊断的 DLBCL 病例和 13 例 DLBCL 细胞系进行全基因组测序,并结合来自 96 例扩展队列的 DNA 拷贝数分析和 RNA-seq 数据,提供了基于全基因组测序的 DLBCL 突变复杂性的视角。我们的分析确定了广泛的基因组重排,包括证据表明存在染色体重排和已知和新的融合转录本。我们发现了新的体细胞点突变的靶基因和疾病中受局灶性体细胞缺失靶向的基因。我们强调了影响编码 S1P 受体和 2 种小 GTPase(GNA13 和 GNAI2)的生发中心 B 细胞受限突变的反复出现,这些突变共同作用于 B 细胞归巢的调节。我们进一步分析了我们的数据,以近似某些反复出现的突变获得的相对时间顺序,并证明持续获得突变和肿瘤内克隆异质性是 DLBCL 的共同特征。这项研究进一步提高了我们对淋巴瘤发生过程和途径的理解,其中一些突变的途径可能表明新的治疗干预途径。

相似文献

1
Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.
Blood. 2013 Aug 15;122(7):1256-65. doi: 10.1182/blood-2013-02-483727. Epub 2013 May 22.
2
The sequence of events in diffuse large B-cell lymphoma.
Blood. 2013 Aug 15;122(7):1097-8. doi: 10.1182/blood-2013-06-506089.
3
Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study.
Clin Cancer Res. 2016 Jun 15;22(12):2919-28. doi: 10.1158/1078-0432.CCR-15-2305. Epub 2016 Jan 27.
4
Characterization of genomic imbalances in diffuse large B-cell lymphoma by detailed SNP-chip analysis.
Int J Cancer. 2015 Mar 1;136(5):1033-42. doi: 10.1002/ijc.29072. Epub 2014 Jul 22.
5
Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma.
Genes Chromosomes Cancer. 2016 Mar;55(3):251-67. doi: 10.1002/gcc.22328. Epub 2015 Nov 26.
6
Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma.
J Clin Exp Hematop. 2016;56(2):71-78. doi: 10.3960/jslrt.56.71.
7
Prediction and characterization of diffuse large B-cell lymphoma cell-of-origin subtypes using targeted sequencing.
Future Oncol. 2021 Nov;17(31):4171-4183. doi: 10.2217/fon-2021-0370. Epub 2021 Jul 27.
9
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.
Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):3879-84. doi: 10.1073/pnas.1121343109. Epub 2012 Feb 17.
10
Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma.
Nature. 2014 Dec 11;516(7530):254-8. doi: 10.1038/nature13765. Epub 2014 Sep 28.

引用本文的文献

2
Disease-specific U1 spliceosomal RNA mutations in mature B-cell neoplasms.
Leukemia. 2025 Jun 30. doi: 10.1038/s41375-025-02667-7.
5
Selective Enhancer Dependencies in MYC-Intact and MYC-Rearranged Germinal Center B-cell Diffuse Large B-cell Lymphoma.
Blood Cancer Discov. 2025 May 5;6(3):233-253. doi: 10.1158/2643-3230.BCD-24-0126.
6
Heterochromatin fidelity is a therapeutic vulnerability in lymphoma and other human cancers.
bioRxiv. 2025 Feb 5:2025.01.31.635709. doi: 10.1101/2025.01.31.635709.
7
Audit of B-cell cancer genes.
Blood Adv. 2025 Apr 22;9(8):2019-2031. doi: 10.1182/bloodadvances.2022009461.
8
Synergistic effect of venetoclax and ibrutinib on ibrutinib-resistant ABC-type DLBCL cells.
Braz J Med Biol Res. 2024 Oct 7;57:e13278. doi: 10.1590/1414-431X2024e13278. eCollection 2024.
9
SETD1B mutations confer apoptosis resistance and BCL2 independence in B cell lymphoma.
J Exp Med. 2024 Oct 7;221(10). doi: 10.1084/jem.20231143. Epub 2024 Sep 5.
10

本文引用的文献

1
Analysis of FOXO1 mutations in diffuse large B-cell lymphoma.
Blood. 2013 May 2;121(18):3666-74. doi: 10.1182/blood-2013-01-479865. Epub 2013 Mar 4.
2
DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer.
Genome Biol. 2012 Dec 22;13(12):R124. doi: 10.1186/gb-2012-13-12-r124.
3
Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma.
Blood. 2013 Feb 28;121(9):1604-11. doi: 10.1182/blood-2012-09-457283. Epub 2013 Jan 7.
4
Genetic heterogeneity of diffuse large B-cell lymphoma.
Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1398-403. doi: 10.1073/pnas.1205299110. Epub 2013 Jan 4.
6
Recurrent targets of aberrant somatic hypermutation in lymphoma.
Oncotarget. 2012 Nov;3(11):1308-19. doi: 10.18632/oncotarget.653.
7
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
Nature. 2012 Dec 6;492(7427):108-12. doi: 10.1038/nature11606. Epub 2012 Oct 10.
9
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.
Nature. 2012 Oct 4;490(7418):116-20. doi: 10.1038/nature11378. Epub 2012 Aug 12.
10
Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas.
Clin Cancer Res. 2012 Oct 1;18(19):5203-11. doi: 10.1158/1078-0432.CCR-12-0845. Epub 2012 Jul 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验